BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2
1844 results:

  • 1. Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma.
    Long AW; Xu H; Santich BH; Guo H; Hoseini SS; de Stanchina E; Cheung NV
    J Hematol Oncol; 2024 Apr; 17(1):20. PubMed ID: 38650005
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Human Epidermal Growth Factor Receptor 2 Overexpression/Amplification in Primary Ovarian Endometrioid Carcinoma.
    Bui CM; Oren A; Balzer B; Maluf H; Medeiros F
    Appl Immunohistochem Mol Morphol; 2024 May-Jun 01; 32(5):222-228. PubMed ID: 38635473
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Codetection of Proteins and RNAs on Extracellular Vesicles for Pancreatic cancer Early Diagnosis.
    He J; Long J; Zhai C; Xu J; Bao K; Su W; Jiang L; Shen G; Ding X
    Anal Chem; 2024 Apr; 96(17):6618-6627. PubMed ID: 38626343
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
    Kim YN; Chung YS; Park E; Lee ST; Lee JY
    Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report.
    Kong YH; Xu ML; Zhang JJ; Chen GQ; Hong ZH; Zhang H; Dai XX; Ma YF; Zhao XR; Zhang CY; Chen RZ; Xing PF; Zhang LY
    World J Gastroenterol; 2024 Mar; 30(9):1237-1249. PubMed ID: 38577174
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Combined KRAS-MAPK pathway inhibitors and her2-directed drug conjugate is efficacious in pancreatic cancer.
    Bulle A; Liu P; Seehra K; Bansod S; Chen Y; Zahra K; Somani V; Khawar IA; Chen HP; Dodhiawala PB; Li L; Geng Y; Mo CK; Mahsl J; Ding L; Govindan R; Davies S; Mudd J; Hawkins WG; Fields RC; DeNardo DG; Knoerzer D; Held JM; Grierson PM; Wang-Gillam A; Ruzinova MB; Lim KH
    Nat Commun; 2024 Mar; 15(1):2503. PubMed ID: 38509064
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice.
    Khoshtinat Nikkhoi S; Yang G; Owji H; Grizotte-Lake M; Cohen RI; Gil Gonzalez L; Massumi M; Hatefi A
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38490714
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Circulating cell-free DNA-based biomarkers for prognostication and disease monitoring in adrenocortical carcinoma.
    Lippert J; Smith G; Appenzeller S; Landwehr LS; Prete A; Steinhauer S; Asia M; Urlaub H; Elhassan YS; Kircher S; Arlt W; Fassnacht M; Altieri B; Ronchi CL
    Eur J Endocrinol; 2024 Mar; 190(3):234-247. PubMed ID: 38451242
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. her2-low and Overexpression in Mucinous Ovarian cancer: Analysis of ASCO/CAP and ToGA Immunohistochemical Scoring.
    Han R; Madariaga A; Gonzalez-Ochoa E; Smith AC; Wang L; Lheureux S; Rouzbahman M
    Int J Gynecol Pathol; 2024 May; 43(3):275-283. PubMed ID: 38436360
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Combined inhibition of her2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer.
    Li W; Zhang K; Wang W; Liu Y; Huang J; Zheng M; Li L; Zhang X; Xu M; Chen G; Wang L; Zhang S
    J Exp Clin Cancer Res; 2024 Feb; 43(1):56. PubMed ID: 38403634
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Clinicopathological pattern of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 over-expression of epithelial ovarian carcinomas in Nigeria.
    Ajani MA; Lawan A; Oke T; Khramtsova G; Nwanji I; Salami A; Awolude O; Ebili H; Onwukamuche ME; Sveen E; Yoshimatsu T; Olopade OI
    Afr Health Sci; 2023 Sep; 23(3):236-244. PubMed ID: 38357171
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Somatic Genomic and Transcriptomic Characterization of Primary Ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.
    Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Bui QH; Matěj R; Laco J; Drozenová J; Fabian P; Škapa P; Špůrková Z; Cibula D; Frühauf F; Jirásek T; Zima T; Méhes G; Kendall Bártů M; Němejcová K; Dundr P
    J Mol Diagn; 2024 Apr; 26(4):257-266. PubMed ID: 38280423
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Thyroid Ultrasound Image Database and Marker Mask Inpainting Method for Research and Development.
    Li X; Fu C; Xu S; Sham CW
    Ultrasound Med Biol; 2024 Apr; 50(4):509-519. PubMed ID: 38267314
    [TBL] [Abstract] [Full Text] [Related]  

  • 14.
    Bao S; Sun N; Li Y; Shu J; Xu J; Zhang Y; Qiu X
    J Int Med Res; 2024 Jan; 52(1):3000605231223426. PubMed ID: 38263931
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. PARP Inhibitors in Breast cancer: a Short Communication.
    Daly GR; AlRawashdeh MM; McGrath J; Dowling GP; Cox L; Naidoo S; Vareslija D; Hill ADK; Young L
    Curr Oncol Rep; 2024 Feb; 26(2):103-113. PubMed ID: 38236558
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues.
    Wong RW; Cheung ANY
    Pathology; 2024 Mar; 56(2):214-227. PubMed ID: 38212229
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Pan-EGFR Inhibitor Dacomitinib Resensitizes Paclitaxel and Induces Apoptosis via Elevating Intracellular ROS Levels in Ovarian cancer SKOV3-TR Cells.
    Lim YJ; Kim HS; Bae S; So KA; Kim TJ; Lee JH
    Molecules; 2024 Jan; 29(1):. PubMed ID: 38202856
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Antibody-Drug Conjugates in Gynecologic cancers.
    Anastasio MK; Shuey S; Davidson BA
    Curr Treat Options Oncol; 2024 Jan; 25(1):1-19. PubMed ID: 38172449
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Immunohistochemical FAP Expression Reflects
    Spektor AM; Gutjahr E; Lang M; Glatting FM; Hackert T; Pausch T; Tjaden C; Schreckenberger M; Haberkorn U; Röhrich M
    J Nucl Med; 2024 Jan; 65(1):52-58. PubMed ID: 38167622
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Multifactor assessment of ovarian cancer reveals immunologically interpretable molecular subtypes with distinct prognoses.
    Guo Y; Li S; Li C; Wang L; Ning W
    Front Immunol; 2023; 14():1326018. PubMed ID: 38143770
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 93.